U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7BrN4O2.C4H11NO
Molecular Weight 348.196
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PAMABROM

SMILES

CC(C)(N)CO.CN1C2=C(N=C(Br)N2)C(=O)N(C)C1=O

InChI

InChIKey=ATOTUUBRFJHZQG-UHFFFAOYSA-N
InChI=1S/C7H7BrN4O2.C4H11NO/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14;1-4(2,5)3-6/h1-2H3,(H,9,10);6H,3,5H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C4H11NO
Molecular Weight 89.1362
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H7BrN4O2
Molecular Weight 259.06
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pamabrom is a diuretic drug, available in over-the-counter medications. The active diuretic ingredient in pamabrom is 8-bromotheophylline. It is used for the relief of temporary water weight gain; bloating; swelling; full feeling associated with the premenstrual and menstrual periods.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.2 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DIUREX

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3685.6 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ACETAMINOPHEN
BROMOTHEOPHYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
46210.49 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ACETAMINOPHEN
BROMOTHEOPHYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
21.35 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ACETAMINOPHEN
BROMOTHEOPHYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
25 mg 1 times / day multiple, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Fixed drug eruption...
AEs leading to
discontinuation/dose reduction:
Fixed drug eruption
Sources:
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 1
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 1
Sources:
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (mild, 1 patient)
Sources:
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (severe, 4 patients)
Vomiting (severe, 4 patients)
Skin rash (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fixed drug eruption Disc. AE
25 mg 1 times / day multiple, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Diarrhea mild, 1 patient
Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 1
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 1
Sources:
Skin rash 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Nausea severe, 4 patients
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Vomiting severe, 4 patients
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Fixed drug eruption caused by pamabrom.
2009 Oct
Patents

Patents

Sample Use Guides

Adults:  Take one (1) capsule after breakfast with a full glass of water.  Dose may be repeated after six (6) hours, not to exceed four (4) capsules per day. Start taking 5 or 6 days before onset of period and continue until desired relief is obtained or end of period. Drink 6 to 8 glasses of water daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:08:30 UTC 2023
Edited
by admin
on Fri Dec 15 15:08:30 UTC 2023
Record UNII
UA8U0KJM72
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PAMABROM
MART.   MI   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
2-AMINO-2-METHYLPROPANOL-1-8-BROMOTHEOPHYLLINATE
Systematic Name English
PAMABROM [VANDF]
Common Name English
PAMABROM [USAN]
Common Name English
Pamabrom [WHO-DD]
Common Name English
PAMABROM [MI]
Common Name English
PAMABROM [USP MONOGRAPH]
Common Name English
8-Bromotheophylline compound with 2-amino-2-methyl-1-propanol (1:1)
Systematic Name English
8-BROMO-3,7-DIHYDRO-1,3-DIMETHYL-1H-PURINE-2,6-DIONE COMPOUND WITH 2-AMINO-2-METHYL-1-PROPANOL (1:1)
Systematic Name English
PAMABROM [MART.]
Common Name English
Classification Tree Code System Code
LIVERTOX 734
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
NCI_THESAURUS C448
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
CFR 21 CFR 310.201
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID80209397
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
NCI_THESAURUS
C81076
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
MESH
C069987
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
RXCUI
54365
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY RxNorm
DRUG BANK
DBSALT002688
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
FDA UNII
UA8U0KJM72
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
CAS
606-04-2
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
SMS_ID
100000079715
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
WIKIPEDIA
Pamabrom
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
EVMPD
SUB14745MIG
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
DAILYMED
UA8U0KJM72
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
ECHA (EC/EINECS)
210-103-4
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
DRUG CENTRAL
2047
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
ChEMBL
CHEMBL316160
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
MERCK INDEX
m8371
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY Merck Index
PUBCHEM
11806
Created by admin on Fri Dec 15 15:08:30 UTC 2023 , Edited by admin on Fri Dec 15 15:08:30 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY